Median salary
$162,750
per year · annualized USD
Typical range
$142.9k – $185k
25th–75th percentile
Disclosing pay
48.6%
34 of 70 roles
Live roles
70
open right now
Associate Director, Global Regulatory Affairs Project Management
Associate Director, Regulatory Affairs Advertising and Promotion
Staff Regulatory Affairs Associate (Digital Health & AI Technologies)
Senior Manager, Regulatory Affairs
Associate Director, Regulatory Affairs
Sr. Manager/Associate Director, Regulatory Affairs
Sr Manager/Assoc Director, CMC Regulatory Affairs
Associate Director, Global Regulatory Affairs Clinical Strategy - Job ID: 1998
| Company | Median | Roles |
|---|---|---|
Iovance Biotherapeutics
|
$150,000 | 7 |
Revolution Medicines
|
$184,500 | 3 |
Mirum Pharmaceuticals
|
$215,000 | 1 |
Ascendis Pharma
|
$205,000 | 1 |
Immunome, Inc.
|
$195,546 | 1 |
Whoop
|
$195,000 | 1 |
Erasca
|
$190,000 | 1 |
Vaxcyte
|
$188,500 | 1 |
| Location | Median | Roles |
|---|---|---|
| Boston | $187,500 | 3 |
| San Francisco | $165,000 | 5 |
See every Regulatory Affairs role
Browse the live listings, or save this search and get alerted the moment a new one posts.
The median salary for Regulatory Affairs roles is $162,750 per year. Most pay falls between $142,875 (25th percentile) and $185,000 (75th percentile), with the broader 10th–90th percentile band running from $106,477 to $195,382.
These figures are computed live from 70 active Regulatory Affairs roles on JobsRadar, of which 34 (48.6%) publish a salary range. Pay is normalized to annualized USD so roles can be compared on equal terms; the highest-paying roles listed above show their original posted currency. Numbers refresh every few hours as new roles are posted and older ones close.
Employers currently hiring well-paid Regulatory Affairs roles include Revolution Medicines, Mirum Pharmaceuticals, Whoop and Kymera Therapeutics.
Salary transparency varies by employer and region, so the disclosing share above reflects only roles that publish pay — not every open position. Use it as a directional benchmark rather than an exact offer.